Iproniazide: Difference between revisions
Rabin Bista (talk | contribs) Created page with "{{Drugbox | verifiedrevid = 443877867 | IUPAC_name = ''N'''-isopropylisonicotinohydrazide | image = Iproniazide wiki str.png | width = 150 <!--Clinical data--> | tradename =..." |
m Protected "Iproniazide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
(No difference)
|
Latest revision as of 16:32, 20 August 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | ? |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Elimination half-life | ? |
Excretion | ? |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C9H13N3O |
Molar mass | 179.219 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Iproniazide |
Articles |
---|
Most recent articles on Iproniazide Most cited articles on Iproniazide |
Media |
Powerpoint slides on Iproniazide |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Iproniazide at Clinical Trials.gov Clinical Trials on Iproniazide at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Iproniazide
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Iproniazide Discussion groups on Iproniazide Patient Handouts on Iproniazide Directions to Hospitals Treating Iproniazide Risk calculators and risk factors for Iproniazide
|
Healthcare Provider Resources |
Causes & Risk Factors for Iproniazide |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Iproniazid (Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class.[1][2] It was discontinued in most of the world in the 1960s, but remained in use in France up until fairly recently.[3]
Iproniazid was originally developed for the treatment of tuberculosis,[1] but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy.[1] Subsequently N-isopropyl addition lead to development as an antidepressant and was approved for use in 1958.[1] It was withdrawn a few years later in 1961 due to a high incidence of hepatitis, and was replaced by less hepatotoxic drugs such as phenelzine and isocarboxazid.[1]
Although iproniazid was one of the first antidepressants ever marketed, amphetamine (marketed as Benzedrine from 1935, for "mild depression", amid other indications)[4] predates it; and frankincense has been marketed traditionally for millennia for, among other things, altering mood, although it was not until 2012 that one of the components of its smoke was found to have antidepressant effects in mice.[5] [6] [7]
Synthesis
Condensation of isoniazid with acetone at the basic nitrogen gives the corresponding Schiff base. Catalytic hydrogenation affords the antidepressant iproniazid.
Prepd by treating isoniazid with isopropyl bromide in absolute alcohol in the presence of sodium.
- Presumably, a third way would be to react the isonicotinic acid ester with acetone hydrazone,[10] the same reactant used in the production of etazolate. Iproniazid would then be obtained after a reduction step.
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Robert A. Maxwell, Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. pp. 143–154. ISBN 0-89603-180-2. ISBN 9780896031807.
- ↑ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical pharmacology. 35 (8): 1381–7. doi:10.1016/0006-2952(86)90285-6. PMID 2870717.
- ↑ Maille F, Duvoux C, Cherqui D, Radier C, Zafrani ES, Dhumeaux D (October 1999). "[Auxiliary hepatic transplantation in iproniazid-induced subfulminant hepatitis. Should iproniazid still be sold in France?]". Gastroenterol. Clin. Biol. (in French). 23 (10): 1083–5. PMID 10592880.
- ↑ Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol. 27 (6): 479–96. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
- ↑ Moussaieff, Arieh; Rimmerman, Neta; Bregman, Tatiana; Straiker, Alex; Felder, Christian C.; Shoham, Shai; Kashman, Yoel; Huang, Susan M.; Lee, Hyosang; Shohami, Esther; Mackie, Ken; Caterina, Michael J.; Walker, J. Michael; Fride, Ester; Mechoulam, Raphael (August 2008). "Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain". 22 (8). The FASEB Journal: 3024–3034. doi:10.1096/fj.07-101865. PMC 2493463. PMID 18492727.
- ↑ Moussaieff, A; Gross, M; Nesher, E; Tikhonov, T; Yadid, G; Pinhasov, A (2012). "Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals". J Psychopharmacol. 26 (12). doi:10.1177/0269881112458729. PMID 23015543.
- ↑ Drahl, Carmen (22 December 2008). "Frankincense And Myrrh". Chemical & Engineering News. 86 (51): 38. doi:10.1021/cen-v086n051.p038. ISSN 0009-2347.
- ↑ Template:Cite DOI
- ↑ McMillan et al., J. Am. Pharm. Assoc. Sci. Ed. 42, 457 (1953).
- ↑ "Simple Accordion with CSS & jQuery by Soh Tanaka". Orgsyn.org. Retrieved 2015-04-12.
Template:Antidepressants
Template:Monoaminergics
Template:Hydrazines
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Unrecognized language
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drug
- Monoamine oxidase inhibitors
- Hydrazides
- Isonicotinamides
- Withdrawn drugs